Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Total Current Liabilities data on file, last reported at $24.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 30.71% year-over-year to $24.5 million; the trailing twelve-month figure through Mar 2026 stood at $24.5 million (down 30.71% YoY), and the FY2025 full-year result was $30.2 million, down 25.75% from the prior year.
• Total Current Liabilities eased to $24.5 million in Q1 2026, from $30.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $48.5 million in Q4 2023 to a low of $22.6 million in Q1 2022.
• A 5-year average of $34.1 million and a median of $33.5 million in 2023 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 76.7% in 2022, while the deepest fall reached 44.26% in 2022.
• Tracing RCKT's Total Current Liabilities over 5 years: stood at $39.2 million in 2022, then grew by 23.84% to $48.5 million in 2023, then fell by 16.12% to $40.7 million in 2024, then decreased by 25.75% to $30.2 million in 2025, then slipped by 19.0% to $24.5 million in 2026.
• Business Quant data shows RCKT's Total Current Liabilities at $24.5 million in Q1 2026, $30.2 million in Q4 2025, and $31.2 million in Q3 2025.